Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare ...
Please provide your email address to receive an email when new articles are posted on . Adults with congenital adrenal hyperplasia receiving an oral corticotropin-releasing factor type 1 receptor ...
Crenessity is expected to be available commercially in approximately 1 week through PANTHERx Rare, a specialty pharmacy. The Food and Drug Administration (FDA) has approved Crenessity TM (crinecerfont ...
The US Food and Drug Administration has approved crinecerfont (Crenessity) for use in combination with glucocorticoids in the treatment of adults and children aged 4 years or older with classic ...
Adrenal hormone function was restored in animal studies, potentially paving the way for a functional cure for primary adrenal insufficiency in humans, according to research presented by Aspect ...
Patients with congenital adrenal hyperplasia (CAH) receiving glucocorticoid therapy showed reduced bone mineral density (BMD), with young adult male patients particularly affected and experiencing a ...
Congenital adrenal hyperplasia (CAH) is a rare genetic condition present from birth. A person with CAH lacks one of the enzymes needed for their adrenal glands to work correctly. Sitting above the ...
Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical congenital ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback